Pfizer Reviews AI-Designed Molecule Amid Strategic AI Push

Pfizer is reviewing a new molecule designed using artificial intelligence, according to CEO Albert Bourla. This move aligns with Pfizer's strategy to integrate AI into its operations, having invested up to $350 million in AI-designed molecules since 2020. The company also announced a collaboration with Boltz biomolecular foundation model team to refine models using Pfizer's data. Meanwhile, Anthropic CEO Dario Amodei claims US AI labs lead Chinese counterparts by 6-12 months, highlighting AI's role in healthcare advancements, according to BeInCrypto.